KPTI Stock — Karyopharm Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.88

Market cap

$42.6M

Cash

$65.1M

Enterprise value

-$22.5M

Balance sheet

Cash	$65.1M
Debt	$0.0M
Net cash	$65.1M
Enterprise value	-$22.5M
Basic shares	22.7M shares
Fully diluted shares	58.3M shares
Fully diluted market cap	$109.6M
Cash per share	$2.87

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading KPTI daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	Selinexor	Phase 2	Myelofibrosis	—
Jan 12 - Feb 23	Selinexor (combination therapy)	Phase 3	Relapsed/Refractory Diffuse Large B-cell Lymphoma	—
Jan 12 - Feb 23	Selinexor	Phase 2	Diffuse Large B-cell Lymphoma	—
May 13 - Jun 24	Selinexor	Phase 2	Multiple Myeloma	—
Jul 13 - Aug 24	Selinexor 60 mg	Phase 2	Myelofibrosis; Moderate Thrombocytopenia; Mild Thrombocytopenia	H2 2026
Feb 12 - Mar 25	Selinexor	Phase 2	Multiple Myeloma, Refractory	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Selinexor (XPOVIO)

Approved · Active Modality: small molecule (XPO1 inhibitor)

Aliases NEXPOVIO

Target XPO1

Partnerships Antengene: Asia-Pacific; Menarini/Berlin-Chemie: Europe, Latin America, Middle East/Africa; KKR (ex-HCRx): revenue interest financing (percentage of selinexor net revenues, capped at $263.3M)

Indications

Multiple myeloma (with bortezomib + dexamethasone, >=1 prior therapy) (Stage not disclosed)
Relapsed/refractory multiple myeloma (with dexamethasone, >=4 prior therapies) (Stage not disclosed)
Myelofibrosis (with ruxolitinib, JAKi-naive) (Phase 3)
Myelofibrosis (monotherapy, JAKi-naive, moderate thrombocytopenia) (Phase 2)
Previously treated multiple myeloma (all-oral, with pomalidomide + dexamethasone) (Phase 3)
Relapsed/refractory DLBCL (Stage not disclosed)
TP53 wild-type advanced/recurrent endometrial cancer (maintenance) (Phase 3)

Catalysts

— August 2026
— H2 2026
— H2 2026

Status note DLBCL accelerated approval voluntarily withdrawn March 2026; company-sponsored trials in that indication being terminated. Myelofibrosis sNDA planned August 2026. Endometrial cancer Phase 3 (XPORT-EC-042) under evaluation.

Eltanexor

Stage not disclosed · Active Modality: small molecule (next-generation XPO1 inhibitor)

Target XPO1

Indications

Myeloproliferative neoplasms (Stage not disclosed)

Status note Company plans to explore development in additional myeloproliferative neoplasms, subject to obtaining additional funding.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Selinexor (combination therapy)
Lead indication	Relapsed/Refractory Diffuse Large B-cell Lymphoma
Lead phase	Phase 3
Active trials	8
Collaborator trials	15

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04442022	Phase 3	Active, not recruiting	Sponsor	KPTI	—	Relapsed/Refractory Diffuse Large B-cell Lymphoma	—
NCT04562389	Phase 3	Active, not recruiting	Sponsor	KPTI	—	Myelofibrosis	—
NCT05611931	Phase 3	Active, not recruiting	Sponsor	KPTI	—	Endometrial Cancer	—
NCT02227251	Phase 2	Active, not recruiting	Sponsor	KPTI	—	Diffuse Large B-cell Lymphoma	—
NCT02343042	Phase 2	Recruiting	Sponsor	KPTI	BMY	Multiple Myeloma	—
NCT05980806	Phase 2	Recruiting	Sponsor	KPTI	—	Myelofibrosis; Moderate Thrombocytopenia; Mild Thrombocytopenia	H2 2026
NCT04414475	Phase 2	Recruiting	Sponsor	KPTI	—	Multiple Myeloma, Refractory	—
NCT04562870	Phase 2	Active, not recruiting	Sponsor	KPTI	—	Myelofibrosis	—
NCT05028348	Phase 3	Active, not recruiting	Collaborator	European Myeloma Network B.V.	—	Multiple Myeloma	—
NCT02436707	Phase 2	Active, not recruiting	Collaborator	Canadian Cancer Trials Group	JNJ	Lymphoma	—
NCT07479979	Phase 2	Recruiting	Collaborator	Natalie Callander	SNY	Relapse Multiple Myeloma; Refractory Multiple Myeloma	—
NCT05530421	Phase 2	Recruiting	Collaborator	University of Miami	—	Relapsed and Refractory Multiple Myeloma	—

Sponsor-matched active trials from ClinicalTrials.gov (8 as sponsor, 15 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 23 active trials for Karyopharm Therapeutics Inc on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	0	-136,736	0.00%	2026-08-14
Ikarian Capital	0	-733,435	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

KPTI — Karyopharm Therapeutics Inc.